Vita Capital II Ltd.
The Artemis Catastrophe Bond and Insurance-linked Securities Deal Directory aims to provide a one-stop resource for information on every cat bond and ILS transaction we hold information on. The content of this Deal Directory is provided as is and there will be some omissions. Help us to keep these cat bond and ILS transaction summaries up to date by contacting us if you see an error or omission that you can correct.
Vita Capital II Ltd. - At a glance:
- Issuer / SPV: Vita Capital II Ltd.
- Cedent / Sponsor: Swiss Re
- Placement / structuring agent/s: Swiss Re Capital Markets Corp. structured the deal.
- Risk modelling / calculation agents etc: ?
- Risks / Perils covered: Extreme mortality
- Size: $362m
- Trigger type: Mortality index
- Ratings: ?
- Date of issue: Apr 2005
- Artemis.bm news coverage: Articles discussing Vita Capital II Ltd. from Artemis.bm
Vita Capital II Ltd. - Full details
Swiss Re has entered into a transaction with Vita Capital II Ltd to receive up to USD 362 million of payments in the event of severe population mortality. Swiss Re experienced strong interest in the life catastrophe bond, which was oversubscribed.
The structure of the Vita Capital II risk coverage is based on a combined mortality index, which applies predetermined weights to the annual general population mortality in the United States, United Kingdom, Germany, Japan and Canada.
The principal of the Vita Capital II notes begins to be at risk if, during a measurement period of any two consecutive years within the risk coverage period, the combined mortality index exceeds predefined percentages of the expected mortality level (120% for Class B, 115% for Class C, 110% for Class D).
The Artemis Catastrophe Bond & Insurance-Linked Securities Deal Directory is copyright © Steve Evans Ltd. Reproduction or publication without permission is not permitted. Use of this information within a commercial product, or for profit, without a license is strictly prohibited. Contact us if you would like to use this content or to discuss licensing.